Actively Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
Led by Sun Yat-sen University · Updated on 2025-03-12
52
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with centrally located early-stage non-small cell lung cancer (NSCLC).
CONDITIONS
Official Title
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed untreated early-stage non-small cell lung cancer (T1-2N0M0), or recurrent disease (rT1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery.
- Centrally located lung cancer.
- Age 18 years or older, regardless of gender.
- ECOG performance status score of 0-2.
- Serum hemoglobin 9 80 g/L, platelets 9 100,000/bcL, absolute neutrophil count 9 1,500/bcL.
- Serum creatinine 6 1.25 times the upper normal limit or creatinine clearance 9 60 ml/min.
- Serum bilirubin 6 1.5 times upper normal limit, AST and ALT 6 2.5 times upper normal limit, alkaline phosphatase 6 5 times upper normal limit.
- FEV1 9 0.5 L.
- Normal CB6 range.
- The patient and their family agree and sign the informed consent form.
You will not qualify if you...
- Any other disease or condition that contraindicates radiotherapy such as active infections, myocardial infarction within 6 months, symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmias.
- Pregnant or breastfeeding women, women who have not undergone pregnancy testing, and pregnant individuals.
- Individuals with substance abuse issues, chronic alcoholism, or AIDS.
- Individuals with uncontrollable seizures or loss of self-control due to psychiatric disorders.
- Individuals with a history of severe allergies or specific sensitivities.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
D
DaQuan Wang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here